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Deletion of the Chemokine Receptor CCR1 Prolongs
Corneal Allograft Survival
Pedram Hamrah,1,2 Satoru Yamagami,1,2,3 Ying Liu,1,2 Qiang Zhang,1 Sudhir S. Vora,1
Bao Lu,4 Craig J. Gerard,4 and M. Reza Dana1
PURPOSE. Many corneal grafts undergo immune rejection, and
current therapies are associated with many side effects. The
purpose of this study was to identify critical chemokine path-
ways involved in generating the alloimmune response to cor-
neal transplants.
METHODS. Orthotopic corneal transplantation was performed in
fully mismatched strains. Cytokine and chemokine receptor
gene expression was determined by the RNase protection
assay. Knockout (KO) strains for chemokine–chemokine re-
ceptors that are upregulated after transplantation underwent
corneal transplantation. Results derived from KO murine hosts
were compared with cyclosporine (Cy) therapy. In addition to
graft survival, graft infiltration, allospecific delayed-type hyper-
sensitivity (DTH), and cytokine expression were compared
among the recipient groups.
RESULTS. Initial experiments revealed gene upregulation of the
chemokine receptors CCR1, -2, and -5 after corneal allorejec-
tion. Although CCR1 KO hosts showed a significant increase in
graft survival compared with wild-type (WT) hosts, allografts in
CCR5, CCR2/CCL3(MIP-1), CXCR3, CXCL10/IP-10, and
CCL3/MIP-1 KO mice did not show a significant improvement
in graft survival. Further, CCR1 KO hosts showed a significantly
higher survival rate than with systemic Cy therapy in WT hosts.
Moreover, graft infiltration by leukocytes and gene expression
of proinflammatory cytokines were reduced in CCR1 KO mice
compared with both Cy treated and untreated WT mice, as was
the induction of allospecific DTH.
CONCLUSIONS. These studies provide, for the first time, evidence
that targeting of specific chemokine pathways can significantly
promote survival of corneal transplants, and suggest that select
deletion or suppression of CCR1 can be a useful therapeutic
target in corneal transplant immunity. (Invest Ophthalmol Vis
Sci. 2007;48:1228–1236) DOI:10.1167/iovs.05-1483
Penetrating keratoplasty has emerged as the most commonform of solid tissue transplantation. Currently, more than
30,000 corneal transplantations are performed each year in the
United States,1 with a 2-year success rate as high as 90% for
uncomplicated first grafts performed in avascular low-risk
beds.2,3 However, these results contrast sharply with the fate
of corneal grafts placed in high-risk host beds in which rejec-
tion rates can exceed 70% to 90%, even with maximum local
and systemic immune suppression.4,5 Eyes at high risk for
corneal transplant failure include those with corneal vascular-
ization, herpes simplex keratitis, and a history of one or more
previously failed grafts.6 Although immune-mediated rejection
remains the leading cause of corneal transplant failure,6,7 sur-
prisingly, pharmacotherapy for corneal transplantation has
changed little over the past several decades, with corticoste-
roids remaining the mainstay of therapy. However, corticoste-
roids are only variably effective in either the prevention or
treatment of high-risk corneal graft rejection and are capable of
inducing cataracts, glaucoma, and opportunistic infections.3,8
Development of safe and targeted new regimens that are effec-
tive in modulating alloimmune responses are therefore a pri-
ority in corneal transplantation.
The destructive immune response to corneal grafts is ef-
fected principally by delayed-type hypersensitivity (DTH)-me-
diating Th1 cells,9,10 recruited into the transplant site by the
local expression of chemokines.11 Chemokines are low-molec-
ular-weight (8–11 kDa) proteins that play a critical role in
immune and inflammatory responses, with nearly 60 chemo-
kine species and over 20 chemokine receptors identified over
the past 10 years.12 Although chemokines are best known for
their ability to stimulate cell migration, they have additional
activities that can contribute to tissue damage and inflamma-
tion, including enhancing T cell activation,13 regulating Th1/
Th2 polarization,14,15 and stimulating macrophage function
and protease secretion.
Work from many laboratories has demonstrated the pres-
ence of specific chemokines during the progression of allograft
rejection. In the cornea, we have shown the expression of
specific species, including CCL2/MCP-1, CCL3/MIP-1, CCL4/
MIP-1, CXCL10/IP-10, and CCL5/RANTES after corneal trans-
plantation.11 These chemokines associate with particular re-
ceptors: CCR1 with CCL3/MIP-1 and CCL5/RANTES; CCR5
with CCL3/MIP-1, CCL4/MIP-1, and CCL5/RANTES; CCR2
with CCL2/MCP-1; and CXCR3 with CXCL10/IP-10. However,
to date there have been no studies in which the relationship
between chemokine or chemokine receptor deficiency and
corneal transplant rejection has been examined. In contrast,
studies in other tissues have revealed that targeted deletion of
CCR1 in complete-major histocompatibility complex (MHC)–
mismatched heart allografts leads to slightly increased survival
compared with wild-type (WT) recipients.16,17 Similar results
have been reported for rat cardiac allografts,18 and rabbit renal
allografts.19 In addition, targeting CCR2 has been shown to
provide transient prolongation of islet cell and heart allograft
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survival.20 When heart allografts are transplanted into CXCL10/
IP-10 (a potent attractant for primed Th1 cells) knockout (KO)
recipients, they are rejected at the same rate as their control
mice. However, when heart allografts from CXCL10/IP-10 KO
donor mice are transplanted, a significantly improved survival
rate was demonstrated, which was associated with the absence
of NK cell infiltration into the grafts.21 Profound increases in
survival rates were also reported in CXCR3 KO murine (the
receptor for CXCL10/IP-10) recipients of heart allografts com-
pared with WT control animals.22 Last, targeting CCL5/
RANTES, a late chemokine, through blocking antibodies to
CCL5/RANTES after cardiac allografting,23 or by using CCR5
KO recipients for cardiac allografts,24 has also shown improve-
ment in graft survival.
In the present study, we used as corneal transplant recipi-
ents murine KO strains of different chemokine–chemokine
receptors that we had correlated with corneal transplantation.
We used this method to determine more precisely which
specific chemokine pathways are most robustly associated
with corneal allograft rejection. We demonstrate, for the first
time, that selected deletion of CCR1, but not CCR5, CCR2/
CCL3(MIP-1), CXCR3, or CXCL10/IP-10, in graft recipients,
leads to significant corneal allograft survival. Further, we dem-
onstrate that the increased survival of allografts in CCR1 KO
recipients is associated with decreased expression of proin-
flammatory cytokines involved in allorejection, a lowered infil-
tration of inflammatory cells into the graft site, and suppressed
DTH responses in grafted hosts.
METHODS
Animals
Unless otherwise noted, BALB/c (H-2d) mice (Taconic Farm, German-
town, NY) were use as donors in the corneal transplantation experi-
ments. For the chemokine receptor mRNA detection studies, C57BL/6
mice were used as recipients. Gene KO strains selected as recipients in
the corneal transplantation experiments, included mice with homozy-
gous deficiency of CCR5 (CCR5/, C57BL/129 background; Jackson
Laboratory, Bar Harbor, ME), CCR2/CCL3(MIP-1) (CCR2/ and
CCL3/MIP-1/, C57BL/129 background), CCL3/MIP-1 (CCL3/MIP-
1/, C57BL/6 background; Jackson Laboratory), CXCR3
(CXCR3/, C57BL/6J background),22 CXCL10/IP-10 (CXCL10/IP-
10/, C57BL/129 background), and CCR1 (CCR1/, C57BL/129
background).25 The wild-type control mice (C57BL/129 and C57BL/6)
were procured originally from the Jackson Laboratory and subse-
quently bred at the Schepens Eye Research Institute animal colony. In
most experiments, male mice were used that were 6 to 12 weeks of
age. Each animal was placed under general anesthesia by intramuscular
injections of ketamine (3–4 mg) and xylazine (0.1 mg) for each surgical
procedure. All protocols were approved by the Institutional Animal
Care and Use Committee. Animals were housed under specific patho-
gen-free conditions and were treated in accordance with the ARVO
Statement for the Use of Animals in Ophthalmic and Vision Research.
Corneal Transplantation
Our standard protocol for murine orthotopic corneal transplantation
was used for these studies.26 Briefly, the center of the donor cornea
(from wild-type BALB/c background mice) was marked with a 2-mm
diameter microcurette, excised with Vannas scissors (Storz Instru-
ments Co., St. Louis, MO) and placed into chilled phosphate-buffered
saline (PBS). The recipient graft bed (chemokine or chemokine recep-
tor KO mice, C57BL/129 WT or C57BL/6 WT mice) was prepared by
excising a 1.5-mm site in the central cornea. The donor button was
then placed onto the corneal bed of recipients and secured with eight
interrupted 11-0 nylon sutures (Sharpoint, Vanguard, TX). Antibiotic
ointment was applied, followed by a 24-hour tarsorrhaphy with 8-0
nylon sutures (Sharpoint). Normal (ungrafted) C57BL/129 or C57BL/6
hosts were used as control mice. Graft sutures were removed in all
cases on day 7. Grafts were evaluated biomicroscopically in a masked
fashion for at least 8 weeks every 2 to 3 days, and graft opacity and
neovascularization were measured according to a standardized scheme
in which grafts with an opacity score of 2 or greater after 3 weeks
were considered rejected.9 Transplants with an opacity score of 3 or
greater after 2 weeks that never cleared by 8 weeks were also regarded
as rejected. Mice with surgical complications (cataract, significant
anterior synechiae or failure to form an anterior chamber by day 2)
were excluded from the study. Immunosuppression with cyclosporine
(Cy; a kind gift from Mohamad H. Sayegh, Harvard Medical School,
Boston, MA) was afforded by dissolving Cy in olive oil and administer-
ing it daily (10 mg/kg intraperitoneally) for 14 days, beginning at the
time of transplantation. Both isografts and normal (ungrafted) host
mice were used as control animals in some experiments.
RNA Preparation and RNase Protection Assay of
Chemokine Receptor Expression and
Cytokine Expression
At select time points after corneal transplantation (n  6–10 corneas
per experiment for cytokine template, and n  4–5 whole eyes for
chemokine receptor template), total RNA was extracted by the single-
step method using RNA-STAT-60 (Tel-Test Inc., Friendswood, TX).
Briefly, whole corneas or whole eyes were homogenized and centri-
fuged to remove cellular debris. The RNA pellet was resuspended in
nuclease-free water and processed together as a group. Detection and
quantification of murine chemokine receptor mRNAs were performed
with a multiprobe RNase protection assay (RPA) system (BD Bio-
science, Franklin Lake, NJ), as recommended by the supplier and as we
have previously described.11 Briefly, a mixture of [-32P] UTP-labeled
antisense riboprobe was generated from the chemokine receptor tem-
plate set mCR-5 (3 weeks after transplantation) and the cytokine
template set mCK1b (2 weeks after transplantation; to analyze the
cytokine profile prerejection; BD Bioscience). Ten micrograms of total
RNA was used in each sample. Total RNA was hybridized overnight at
56°C with 300 pg of the 32P-anti-sense riboprobe mixture. After puri-
fication by ethanol precipitation, the samples were resolved on 5%
polyacrylamide sequencing gels. The gels were dried and subjected to
autoradiography. Protected bands were observed after exposure of
gels to x-ray film. The bands were quantitated by densitometric analysis
and normalized to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). Both isografts and normal (non-grafted) host mice were used
as control animals. All samples were analyzed in duplicate.
Subconjunctival Injection of Anti-RANTES
Blocking Antibody
Corneal transplantation (n  33) was performed from C57BL/6 mice
(donor) to BALB/c mice (recipient) as just detailed. After routine
general anesthesia, subconjunctival injection was performed with a
100-L glass syringe (Hamilton Co., Reno, NV) and a 30-gauge needle
(n 10). A total of 5 L (5 g each) of rat anti-mouse CCL5/RANTES
blocking Ab (clone 53405; R&D Systems, Minneapolis, MN) was in-
jected on the day of surgery, and at 4, 7, 10, 14, 21, and 25 days after
surgery. The same amount of rat IgG2a (clone 54447; R&D Systems)
was used as a control (n 12). The remaining mice (n 11) did not
receive any treatment.
Histopathological Evaluation of Graft Infiltration
For the measurement of leukocytic infiltration of grafts before any
clinical signs of rejection, wild-type and KO mice were killed at days 7
and 14 (each, n 5) after transplantation and the grafted eyes were
enucleated. The enucleated eyes were fixed with 10% paraformalde-
hyde, embedded in paraffin, sectioned, and stained with hematoxylin
and eosin. At least 10 sections per eye were evaluated morphologically
by light microscopy in a masked fashion, and the total number of
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leukocytes, polymorphonuclear cells, and mononuclear cells was
counted per section.
Antibodies and Immunohistochemistry
The immunohistochemical staining procedures were performed using
the following Abs: purified hamster anti-mouse CD11c (HL3, dendritic
cell marker); FITC-conjugated hamster anti-mouse CD3-e (145-2C11;
T-lymphocyte marker); purified rat anti-mouse CD45 (30-F11, pan-
leukocyte marker); purified goat anti-mouse CCR1 (C-20; Santa Cruz
Biotechnology, Santa Cruz, CA), and purified goat anti-mouse CCR5
(M-20; Santa Cruz Biotechnology). The secondary antibodies were
rhodamine-conjugated goat anti-rat IgG, FITC-conjugated donkey anti-
goat IgG (Santa Cruz Biotechnology), and Cy5-conjugated goat anti-
Armenian hamster IgG. Isotype controls included rat IgG2b and ham-
ster IgG. All primary and secondary mAbs (except where noted) and
isotype-matched controls were purchased from BD PharMingen (San
Diego, CA).
For the histochemical studies, normal and grafted corneas were
excised from C57BL/129 or CCR1 KO mice, and the epithelium was
removed from the stroma as described before.27 Full-thickness corneal
stromal tissue (for CCR1, CCR5, CD11c, and CD45), corneal epithelial
sheets28 (for CCR1, CCR5, CD11c, and CD45), or 8-m frozen sections
(for CD3) were fixed in acetone for immunofluorescence staining as
previously described.29 In brief, sections, flatmounts, or epithelial
sheets were immunostained with primary antibodies or isotype-
matched control antibodies for 2 hours. Thereafter, the samples were
incubated with secondary antibodies for 1 hour if necessary. All stain-
ing procedures were performed at room temperature, and each step
was followed by three thorough washings in PBS for 5 minutes each.
The samples were covered with mounting medium (Vector Laborato-
ries, Burlingame, CA) and analyzed by confocal laser scanning micro-
scope (Leica TCS 4D; Lasertechnik, Heidelberg, Germany). At least five
sections (n  3 animals) or three corneal flatmounts were analyzed for
each experiment.
Assessment of Donor-Specific DTH
At 3 weeks after corneal transplantation, 1  106 irradiated (2000 rad)
spleen cells from donors syngeneic with the corneal grafts (BALB/c), in
10 L Hanks’ balanced salt solution, were injected into the right
pinnae of corneal hosts.30 As a control, a similar number of spleen cells
were injected into the ear pinnae of wild-type and CCR1 KO mice that
had been immunized 1 week earlier by intraperitoneal injection of
10  106 spleen cells of the appropriate allogeneic strain. All experi-
mental and control groups consisted of five animals. After 24 and 48
hours, ear thickness was measured in a masked fashion with a low-
pressure micrometer (Mitutoyo; MTI Corp., Paramus, NJ). Allospecific
ear swelling was expressed as follows: specific ear swelling (24-hour
measurement of right ear  0 hour measurement of right ear) 
(24-hour measurement of left ear  0 hour measurement of left ear) 
103 mm. Ear-swelling responses are presented as mean SE. Because
results at 24 and 48 hours were similar, only 24-hour data are pre-
sented. Both isografts as well as normal (non–graft recipient) host mice
were used as control subjects.
Statistical Analyses
Rates of corneal graft survival were plotted as Kaplan-Meier survival
curves and were compared using the log-rank (Mantel-Cox) or Stu-
dent’s t-test for specific time point for KO mice or Cy-treated mice
compared with the WT control samples. mRNA expression levels are
given as the mean  SE. Student’s t-test was used for comparison of
DTH responses and graft infiltration. Statistical significance was de-
fined as P  0.05.
RESULTS
Chemokine Receptor Gene Expression in
High-Rejecting C57BL/6 and Low-Rejecting
BALB/c Hosts
Orthotopic corneal transplantation was performed in two re-
cipient wild-type murine models characterized by a low
(C57BL/6 to BALB/c; 50% rejection; median time to rejection,
28 days) or high (BALB/c to C57BL/6; 90% rejection; median
time to rejection, 21 days) rate.31 Naı¨ve mice and isografts
were used as control subjects. Whole eyes were excised 3
weeks after transplantation, and RPA was performed to detect
increased chemokine receptor gene expression. Figures 1A–C
demonstrate the results of the RPA autoradiograph and the
quantity of chemokine receptor mRNA normalized to GAPDH.
There was an increased expression of CCR1, -2, and -5 mRNA
in rejected allografts, both in the C57BL/6 (Fig. 1B) and BALB/c
hosts (Fig 1C). CCR1 and CCR2 mRNA were also minimally
detected in accepted allografts in both models (Figs. 1B, 1C).
Isografts and naı¨ve mice demonstrated no increase in chemo-
kine receptor expression.
Corneal Graft Survival in Chemokine and
Chemokine Receptor KO Mice
Given the overexpression of CCR1, -2, and -5 genes, and the
previously demonstrated gene overexpression of several of
their ligands and the CXCL10/IP-10 gene (a ligand for CXCR3)
in rejected allografts,11 we tested the effects of genetic dele-
tion of CCR1, CCR2, CCR5, CXCR3, CCL3/MIP-1, and
CXCL10/IP-10 on corneal graft survival in KO mice, using fully
mismatched strains. The results are summarized in Table 1.
Corneal allografts in CCR5 KO mice showed no improved
survival at 8 weeks (11%) compared with WT mice (10%; P 
0.94). There was, however, a slight delay in rejection as evi-
denced by the survival rate at 4 weeks after transplantation
(44% in CCR5 KO mice versus 20% in WT mice; P  0.28).
Graft survival in CCR2/CCL3(MIP-1) double-KO, CCL3/
MIP-1 KO, CXCL10/IP-10 KO, and CXCR3 KO mice did not
show any improvement compared with graft survival in the
respective WT mice at any time point studied (Table 1). How-
ever, corneal grafts in CCR1 KO mice showed a significantly
improved threefold graft survival compared with WT hosts.
The survival rate in CCR1 KO hosts (C57BL/6 background) was
100% at 4 weeks and 60% at 8 weeks compared with a survival
rate of 30% and 20% in WT mice, respectively (P  0.001 and
P  0.004 respectively).
Corneal Allograft Survival in CCR1 KO Hosts
Compared with Systemic Cy Treatment
To evaluate the corneal graft survival in CCR1 KO mice com-
pared with conventional therapy, we treated wild-type hosts
with a 14-day course of Cy at 10 mg/kg per day intraperitone-
ally17 and compared the graft survival rate in these mice to
CCR1KO hosts (Fig. 2). Corneal transplants were followed
daily for 10 weeks. Corneal graft survival in CCR1 KO hosts
was significantly higher at 10 weeks (60%) compared with WT
mice treated with Cy (30%; P 0.01) and untreated mice (20%;
P  0.002).
Role of CCL5/RANTES in Corneal
Allograft Rejection
To determine the role of CCL5/RANTES, a ligand to both CCR1
and -5 receptors, in corneal allograft rejection, blocking exper-
iments were performed after corneal transplantation with sub-
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conjunctival injection of RANTES neutralizing Ab. Subconjunc-
tival injections were performed on days 0, 4, 7, 10, 14, 21, and
25. There was no improvement in corneal graft survival in mice
treated with a CCL5/RANTES-blocking Ab (n 10; 6/10
[60.0%] rejected) compared with mice injected with isotype
control IgG2a (n 12; 7/12 [58.3%] rejected) or untreated
control animals (n 11; 5/10 [50.0%] rejected).
Profile of Corneal Leukocyte Infiltration
To elucidate the potential mechanisms by which the deletion
of CCR1 influences corneal graft outcome, graft infiltration
profiles were compared in grafts performed in CCR1 KO mice
and in Cy-treated and untreated WT mice. Corneas were ex-
cised at 7 and 14 days after transplantation, and sections were
FIGURE 1. CC chemokine receptor
gene expression levels 3 weeks after
corneal transplantation. Autoradiog-
raphy data for C57BL/6 and BALB/c
hosts are shown in (A). On the basis
of the migration pattern of the undi-
gested probes, specific bands were
identified for each chemokine. Den-
sitometric analyses normalized to
GAPDH are shown in (B) for
C57BL/6 hosts and in (C) for BALB/c
hosts. Vertical axes indicate arbitrary
units based on densitometry. Overex-
pression of CCR1, -2, and -5 mRNA
was observed 3 weeks after corneal
transplantation in both models. Two
sets of results on separate experi-
ments were analyzed, and averaged
density was shown as the results of
densitometric analysis. 1, naı¨ve mice;
2, isografts; 3, accepted allografts; 4,
rejected allografts.
TABLE 1. Survival of Fully Mismatched Corneal Allografts in Different Strains of Chemokine/Chemokine
Receptor KO Recipients and Controls (percent survival)
Strain (Animals)
Weeks after Surgery
2 4 8
CCR5-KO 9/9 (100) 4/9 (44) 1/9 (11)
CCR5-WT 9/10 (90) 2/10 (20) 1/10 (10)
P 0.36 0.28 0.94
CCR2/CCL3(MIP-1)-KO 11/11 (100) 1/11 (9) 0/11 (0)
CCR2/CCL3(MIP-1)-WT 9/10 (90) 2/10 (20) 1/10 (10)
P 0.31 0.5 0.31
CCL3/MIP-1-KO 6/8 (75) 0/8 (0) 0/8 (0)
CCL3/MIP-1-WT 6/8 (75) 0/8 (0) 0/8 (0)
P 1 1 1
CXCL10/IP-10-KO 6/10 (60) 0/10 (0) 0/10 (0)
CXCL10/IP-10-WT 8/10 (80) 0/10 (0) 0/10 (0)
P 0.17 1 1
CXCR3-KO 7/7 (100) 7/7 (100) 2/7 (29)
CXCR3-WT 7/7 (100) 6/7 (86) 3/7 (43)
P 1 0.36 0.36
CCR1-KO 10/10 (100) 10/10 (100) 6/10 (60)
CCR1-WT 7/10 (70) 3/10 (30) 2/10 (20)
P 0.08 0.001 0.037
* CCR1-KO data are plotted in Figure 2.
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subjected to hematoxylin and eosin (H&E) staining for mor-
phologic enumeration of mononuclear and polymorphonu-
clear (PMN) cells (Fig. 3). Leukocyte (PMN and mononuclear)
infiltration decreased in all three models between days 7 and
14. However, there was a profound (50%) decrease in the
number of leukocytes infiltrating transplants placed in CCR1
KO mice compared with WT mice and Cy-treated mice (Fig.
3A; P  0.05) and this was evident for both PMN (Fig. 3B; P 
0.001) and mononuclear (Fig. 3C; P  0.05) cells. Further, the
difference in mononuclear cell infiltration was significant (P 
0.05) between the two groups at both time points studied (Fig.
3C). Results for rejected WT mice are given at day 14 only for
comparison. Although macrophages are known to constitute
the prominent early component of graft infiltration, we also
evaluated the effect of CCR1 gene deletion on the number of
infiltrating T cells, based on the membrane expression of CD3
on days 6 and 12 after transplantation, before overt clinical
graft rejection, which started at approximately around day 14
(Fig. 4). At day 6 after transplantation, CD3 cells were nearly
absent in all groups (Fig. 4A) with no significant difference
between the WT mice compared with CCR1 KO mice (P 
0.058) or WT mice compared with WT mice treated with Cy
(P  0.11). By day 12, there was a significant influx of CD3
cells into the WT hosts (Fig. 4B), whereas CCR1 KO (P 
0.014; compared with WT mice) and Cy-treated (P  0.003;
compared with WT mice) groups demonstrated no such influx.
The difference between CCR1 KO mice compared with Cy-
treated WT mice was not significant at both 6 (P  0.051) and
12 (P  0.133) days after transplantation.
CCR1 Expression on Graft Cells
Evaluation of infiltrating leukocytes demonstrated that most of
these cells constitute mononuclear cells that include macro-
phages and dendritic cells (DCs). Normal corneas were excised
form WT mice and stromal wholemounts, as well as epithelial
sheets, were double stained for CD45 (pan-leukocyte marker)
or CD11c (DC marker) and CCR1 or CCR5, and evaluated by
confocal microscopy. Results demonstrated the absence of
CCR1 and CCR5 expression by stromal DCs and epithelial LCs
in normal ungrafted corneas (data not shown). Next, corneal
transplantation was performed in WT mice, and the corneas
were excised at 3 and 6 days after transplantation. Corneal
stromal wholemounts and epithelial sheets were double
stained for CD45 or CD11c and CCR1 or CCR5 (Fig. 5). Al-
though at 3 days no staining was detected for CCR1 or CCR5 in
either epithelium or stroma, CCR 5 expression was detected at
day 6 after transplantation in the epithelium (Figs. 5A–C),
similar to CCR5 expression on epithelial LCs as previously
demonstrated.32 CCR1 expression was not detected at any
time point studied on epithelial LCs (Figs. 5D–F). An increase
in CCR5 (Figs. 5G–I) and CCR1 (Figs. 5J–L) expression was
detected at days 3 and 6 after transplantation on stromal
CD11c DCs (Figs. 5G–L).
Suppression of Th1 Cytokines and DTH
Responses in CCR1 KO Recipients
To assess the extent to which deletion of CCR1 gene expres-
sion affects production of Th1 cytokines before rejection of
allografts at 3 weeks after transplantation, corneas were ex-
cised 2 weeks after transplantation (before the onset of al-
lorejection) and examined for Th1 cytokine gene expression
FIGURE 3. Leukocyte infiltration into corneal allografts. Allogeneic
(BALB/c) corneal grafts were performed in CCR1 KO (n  10), un-
treated WT (n  10), and Cy-treated WT mice (n  10). At days 7 (n
 5 per group) and 14 (n  5 per group), corneas were harvested and
the leukocytic infiltration quantified (A) and subtyped morphologically
with light microscopy for polymorphonuclear cells (PMN) (B) and
mononuclear cells (C). Data depicted as the mean  SE. Significantly
decreased infiltration of total leukocytes, PMN and mononuclear cells
was observed into CCR1 KO hosts compared with Cy-treated and
untreated wild-type hosts at both time points studied.
FIGURE 2. Kaplan-Meier graft survival curves for allogeneic corneal
transplants. Grafts are shown for CCR1 knockout hosts (blue), wild-
type mice with cyclosporin treatment (red), and wild-type control
mice (black). There was a significant delay in rejection in CCR1 KO
hosts. Moreover, there was a significantly higher survival rate in CCR1
KO mice compared with cyclosporin-treated and control mice.
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by RPA, in both CCR1 KO and WT recipients. Results demon-
strated a suppression of Th1 cytokines interleukin (IL)-2 and
interferon (IFN)- in CCR1 KO mice compared with WT hosts
(Fig. 6). Although the level of IL-2 expression in CCR1 KO
recipients 2 weeks after transplantation was negligible and
comparable to that in naı¨ve mice, the level of IFN- was
reduced by half in CCR1 KO recipients compared with WT
mice (Fig. 6).
To examine whether CCR1 KO transplant recipients are
sensitized against donors, we performed allospecific DTH stud-
ies among CCR1KO and WT recipients (Fig. 7). Naı¨ve mice
served as negative controls, and mice that were previously
sensitized to donor cells served as positive controls. The DTH
studies were performed at 3 weeks after transplantation, when
graft recipients are known to have a positive DTH response.
Compared with WT hosts (mean, 93 m), CCR1 KO hosts
(mean, 52 m) demonstrated a significant (P  0.05) decrease
in DTH alloreactivity, indicating suppressed sensitization in
CCR1 KO mice (Fig. 7).
DISCUSSION
Corneal transplantation has restored sight to millions of blind
people worldwide, but there have been no major changes in
pharmacotherapy for decades since the advent of corticoste-
roids and most high-risk grafts are still rejected despite maxi-
mum anti-inflammatory therapy. Deletion or blockade of mo-
lecular mediators of alloimmunity potentially offers the
possibility of more precise inhibition with fewer side effects.
The deletion or blockade of chemokines has been partially
successful in several organ transplantations,16–24,33 but mech-
anistic studies unraveling chemokine pathways in corneal
transplantation have not been performed thus far. The present
study demonstrates, for the first time, that targeting the che-
mokine receptor CCR1 can lead to a significant increase in
long-term corneal graft survival.
Our previous work evaluating patterns of chemokine ex-
pression in the late phase of corneal transplant rejection iden-
tified CCL5/RANTES, CCL3/MIP-1, CCL4/MIP-1, CCL2/
MCP-1, and CXCL10/IP-10 mRNA overexpression, though the
functional relevance of these findings in the immunopathogen-
esis of graft rejection was not investigated.11 In this study, we
focused on the expression and functional role of specific CC
and CXC chemokine receptors implicated in corneal alloimmu-
nity by virtue of their overexpression and examined the effect
of selective gene deletion to demonstrate that CCR1 suppres-
sion had a significant effect in promoting allograft survival,
even beyond that seen with Cy administration.
In light of our previous findings, the current findings may be
surprising, since the deletion of CCR1 led to a significantly
improved allograft survival, whereas deletion of other chemo-
kine receptors, whose ligands were upregulated after graft
rejection did not. Although the results obtained by Yamagami
et al.11 were obtained from whole eyes that included both
donor and recipient tissue, the current experiments were per-
formed using recipient KO mice. Hancock et al.21 showed
elegantly that when CXCL10/IP-10 KO allografts were trans-
planted into WT recipients, a significantly improved survival
rate was demonstrated. In contrast, the survival was not im-
proved when WT allografts were transplanted into CXCL10/
IP-10 KO recipients. Therefore, the KO mice used herein as
recipients might demonstrate improved corneal graft survival if
used as donors. In addition, there is a high level of promiscuity
in the chemokine system. Despite this promiscuity, there are
functional differences when the same ligands bind to different
receptors. This is, in part, because different chemokine recep-
tors are expressed by different cell types. We show here that in
addition to CCR1 KO mice, the CCR5 KO mice recipients
(CCR1 and CCR5 share ligands) demonstrated a delayed rejec-
tion compared with WT mice. The role of CCR5 and CCL5/
RANTES in recruitment of MHC class II-positive LCs in the
corneal epithelium has been shown by us recently.30 Our
current data suggest that while some stromal DCs also express
CCR5, they are the only antigen-presenting cell (APC) popula-
tion that express CCR1, because epithelial LCs do not express
this receptor. This finding underscores the importance of in-
trastromal graft infiltration by APCs in corneal alloimmunity.
Moreover, the different expression patterns of CCR1 and CCR5
by the epithelial and stromal DCs could explain the different
results obtained between CCR1 KO and CCR5 KO mice in this
study. Similarly, previous studies have shown that chemotactic
migration of monocytic-derived DCs (like corneal stromal
DCs), is abolished with Abs to CCR1, but not with Abs to
CCR5.34 The different roles of epithelial LCs and stromal DCs
are further confirmed by the fact that, although CCL5/RANTES
blockade led to a CCR5-mediated suppression in LC migration
after inflammation, CCL5/RANTES blockade alone did not im-
FIGURE 4. T-cell infiltration into corneal allografts. Allogeneic
(BALB/c) corneal grafts were performed in CCR1 KO, cyclosporin-
treated, and untreated WT mice. At days 6 (A) and 12 (B), corneas were
harvested and T-cell infiltration quantified based on immunohisto-
chemical staining with anti-CD3. At day 6 after transplantation (A),
CD3 cells were nearly absent in all groups. By day 12, there was
significant influx of CD3 cells into WT hosts (B), whereas CCR1 KO
and cyclosporin-treated groups demonstrated no such influx. Data
depicted as the mean  SE; *P  0.014, **P  0.003, NS  P  0.05.
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prove corneal graft survival, suggesting that other chemokines
are involved in the CCR1-mediated corneal allograft rejection.
Corneal allograft rejection is primarily mediated by CD4
Th1 cells.35–37 This study demonstrates the mediation of Th1
responses by CCR1, as CCR1 deletion was associated with a
reduced influx of T cells into the cornea, as well as abolished
gene expression of Th1 cytokines IL-2 and IFN-. IFN-, a
product primarily of Th1 cells, can induce production of Th1-
attracting chemokines, whereas antagonizing Th2-attracting
chemokines.38 CXCL10/IP-10 for instance, is induced by IFN-
and is expressed abundantly in rejected corneal transplants.11
IFN- can also synergize with IL-1 and TNF- to stimulate
chemokine production, and as such, demonstration of the
critical role of CCR1 in mediating corneal allograft rejection
provides indirect confirmation for our previous work implicat-
ing IL-1 and TNF- in alloimmunity.30,32,35,39,40
Leukocyte recruitment into the corneal graft is a major
component of the early alloimmune response, as is the case for
other tissue grafts. A recent study demonstrated in a renal
inflammatory model that CCR1, but not CCR5, is required for
leukocyte recruitment.41 Further, Eis et al. demonstrated
through the use of the CCR1- antagonist BX471 and CCR5-
blocking antibodies that CCL5/RANTES-induced arrest of
monocytes and T cells was predominantly mediated by CCR1
but not CCR5.41 In addition, neutrophils have been reported to
express CCR1, explaining our observation that CCR1 blockade
has a profound effect on neutrophil infiltration into corneal
grafts. Earlier studies have shown that neutrophils from CCR1
KO mice are nonresponsive to CCL3/MIP-1, suggesting that
CCR1 may be the dominant CCL3/MIP-1 binding receptor
subtype in these cells.
The process of antigen presentation is an indispensable step
in the corneal alloimmune response, and our knowledge re-
garding the presence and importance of corneal APCs has
evolved over the past years.42,43 Here, we confirm our previ-
ous findings that CCR5, but not CCR1, is expressed on
FIGURE 5. Immunohistochemical
studies of epithelial sheets and
stroma by confocal microscopy for
CCR1 and -5. On day 6 after corneal
transplantation, CD11c LCs (red)
(A, D) expressed CCR5 (green) (B),
but not CCR1 (green) (E). Den-
dritic cells (red) (G, J) expressed
CCR5 (green) (H) and CCR1
(green) (K) in the corneal stroma.
(A, D, G, J) CD11c (red), (B, H)
CCR5 (green), (E, K) CCR1
(green), (C, F, I, L) merged,
costained (yellow). (A–F) Stained
epithelial sheets; (G–L) stained
stromal wholemounts.
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CD11cCD11b epithelial LCs during inflammation.32 Fur-
ther, we noted that stromal DCs (that are uniformly CD11b)
are able to express both CCR1 and -5 during inflammation, and
hence are the only APCs that express CCR1 in the cornea.
CCR1 and -5 are responsible for the recruitment of immature
DCs in a variety of inflamed tissues, through the chemokines
CCL3/MIP-1, CCL5/RANTES, and CCL7/MCP-3. Once acti-
vated, DCs secrete high levels of CCL3/MIP-1 (not made
constitutively by resident corneal cells)11,44 that lead to addi-
tional recruitment of inflammatory cells. This is a likely expla-
nation for the significant effect of CCR1 (but not CCR5) block-
ade on allograft infiltration and rejection, indicating the
important role of stromal DCs in the alloimmune response. In
addition, given the critical role of APCs in initiating the alloim-
mune response, the decreased recruitment of DCs observed in
the absence of CCR1 inhibits the initiation and sustained Ag
sampling, thereby decreasing or delaying the priming of effec-
tor T cells. The role of CCR1, but not CCR5, in regulating the
interaction of monocytic-derived DCs and T cells has been
demonstrated in the past.34
It is important to address the potential limitations in this
study. First, we primarily extracted RNA from whole-eye ho-
mogenates for analysis of chemokine receptor mRNA to pre-
vent the problems faced with the very small quantities of RNA
extracted from the murine cornea. The use of only corneal
RNA would have translated into a significant increase in the
number of animals used. We had faced similar problems in our
previous studies where we confirmed that the expression of
specific chemokine mRNA after allograft rejection that was
reflected in the whole-eye data was similar to data in the
corneal microenvironment.11 Therefore, although the RPA
analysis of whole eyes has the disadvantage of not limiting the
assay to the cornea alone, it has the distinct advantage of also
assaying chemokine species expressed by other (noncorneal)
structures in the anterior segment, such as the vascularized
tissues in and around the iris root that also materially contrib-
ute to leukocyte infiltration into the anterior eye structures,
including the cornea and anterior chamber after corneal trans-
plantation.
Second, although the deletion of CCR1 clearly modulated
corneal graft rejection in CCR1 gene-targeted recipient mice,
some mice still rejected their corneal grafts. Although leuko-
cyte recruitment into a corneal graft is a major component of
the alloimmune response, corneal allograft rejection is con-
trolled by CD4 T cells. We demonstrated here that corneal
allograft survival can be prolonged through a substantial de-
crease in the number of infiltrating T cells in CCR1 KO recip-
ients compared with WT recipients. However, the fact that
some CCR1 KO recipients still rejected their allografts, dem-
onstrates that CCR1-mediated mechanisms, despite their signif-
icance, alone cannot entirely account for the alloimmune re-
sponse. Finally, although we used CCR1 KO recipients in this
study to analyze the role of CCR1, we have not used an
inhibitor/antagonist of CCR1 in WT recipients to confirm these
results, and therefore we cannot comment on alternate (e.g.,
compensatory) pathways that may exist in the CCR1 KO mice.
However, notwithstanding this limitation, it is important to
emphasize that these compensatory pathways are typically
more problematic in a setting of “false-negative” data with KO
animals, in which they can compensate for the lack of a gene
through changed expression of other gene products, rather
than in this case in which specific gene deletion led to a
significant change in outcome.
In summary, this study is the first to identify the role of a
critical chemokine receptor in corneal alloimmunity. Targeting
CCR1 alone or its ligands may prove to be an effective strategy
to suppress the rejection of corneal transplants, thus reducing
FIGURE 6. Th1 cytokines are de-
creased in CCR1 KO hosts. Corneas
of CCR1 KO and WT hosts were ex-
cised 2 weeks after transplantation,
and RPA was performed to detect
gene expression levels of Th1 cyto-
kines in the transplanted corneas be-
fore rejection. (A) Autoradiograph
data. On the basis of the migration
pattern of the undigested probes,
specific bands were identified for
each cytokine. Densitometric analy-
ses normalized to GAPDH are shown
in (B) for CCR1 KO hosts and in WT
hosts. Results demonstrate suppres-
sion of both IL-2 and IFN- in CCR1
KO mice compared with WT mice.
FIGURE 7. Donor-specific DTH in CCR1 KO hosts is decreased. Ear
swelling of naı¨ve (negative control), subcutaneous primed (positive
control) WT hosts, and CCR1 KO hosts were measured with a micro-
meter 24 and 48 hours after ear challenge by donor cells 3 weeks after
transplantation. CCR1 KO hosts demonstrated a significantly sup-
pressed degree of donor-specific ear swelling (DTH) compared with
control hosts (*P  0.05).
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the risk of the myriad toxic side effects of alternative nonspe-
cific immunosuppressive drugs.
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